Emergent BioSolutions Inc.
For the period ended Aug 5, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2026 · Filed Aug 5, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · FOOTNOTES
FOOTNOTES
(1)All financial information included in this release is unaudited.
(2) See“Non-GAAP Financial Measures” and the “Reconciliation of Non-GAAP Financial Measures” tables for the definitions and reconciliations of Company-wide non-GAAP financial measures to the most closely related GAAP financial measures. Reconciliations of segment non-GAAP financial measures are included within the reportable segment tables. In the first quarter of 2026 we revised our calculations of these measures to exclude the impact of stock-based compensation expense, as this is a non-cash expense that is not related to our operating performance. The updated ranges for our 2026 forecast reflect this adjustment.
(3)Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with GAAP.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.